Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Novartis
Ludwig Institute for Cancer Research
Pfizer
Novartis
Stanford University
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
Astellas Pharma Inc
NYU Langone Health
Case Comprehensive Cancer Center